Dolutegravir + Rilpivirine Suppliers & Bulk Manufacturers
Available Forms: Tablet
Available Strengths: 50 mg / 25 mg
Reference Brands: Juluca(EU & US)
Category: Anti Viral
Dolutegravir + Rilpivirine, sold as Juluca, is a once-daily, two-drug HIV-1 maintenance therapy for virologically suppressed adults. It offers effective viral suppression with fewer side effects and is approved by the FDA and EMA. Dolutegravir + Rilpivirine is available in Tablet and strengths such as 50 mg / 25 mg. Sourced from GMP-certified and ISO-compliant manufacturers, this API meets global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical formulation and commercial manufacturing, Dolutegravir + Rilpivirine is supplied in bulk quantities with complete regulatory support including DMF, COA, and MSDS.
| Technical Specifications & Supply Details | |
|---|---|
| Lead Time | 7 to 60 days (depending on batch size & schedule) |
| MOQ | As per manufacturer’s batch size |
| COA | Available with every batch |
| Regulatory Dossier / DMF | Available upon request |
| Export Documentation | FSC, COA, Manufacturing License, Product Permission |
| Standards | IP, BP, USP |
| Certifications | WHO-GMP, EU-GMP, USFDA (as applicable) |
Dolutegravir + Rilpivirine can be exported to over 30 countries across Asia, Africa, Europe, and Latin America. Flexible packaging, competitive pricing, and a verified supplier network make Pharmatradz a trusted sourcing partner for pharmaceutical companies and contract manufacturers worldwide.
Product Description:
Dolutegravir + Rilpivirine, marketed as Juluca, is a once-daily, two-drug regimen for the maintenance treatment of HIV-1 infection. It combines Dolutegravir, an integrase strand transfer inhibitor (INSTI), and Rilpivirine, a non-nucleoside reverse transcriptase inhibitor (NNRTI), to effectively suppress HIV replication. Approved by the US FDA and EMA, Juluca is intended for adults who are virologically suppressed (HIV-1 RNA <50 copies/mL) on a stable antiretroviral regimen with no history of treatment failure. Juluca offers a simplified treatment option with fewer drugs, reduced side effects, and excellent tolerability, making it ideal for long-term HIV management.
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Frequently Asked Questions
Dolutegravir and rilpivirine are used together as a complete two-drug regimen for the treatment of HIV-1 infection in adults. It is prescribed for patients who are already virologically suppressed on a stable antiretroviral therapy and want to switch to a simpler regimen. The combination maintains viral suppression and helps reduce pill burden.
It is made from Dolutegravir, an integrase strand transfer inhibitor, and Rilpivirine, a non-nucleoside reverse transcriptase inhibitor. Together, these two agents block HIV replication through different mechanisms, providing effective dual therapy.
The trade name for this combination is Juluca.
Juluca is manufactured by ViiV Healthcare in collaboration with Janssen Therapeutics, which provides the rilpivirine component.
The generic name is Dolutegravir + Rilpivirine.
The brand name is Juluca.
It is manufactured in the UK and Europe by ViiV Healthcare, with global distribution, and generic versions are produced in India by licensed manufacturers for developing markets.
Related Products
Maraviroc
Strength:
150 mg, 300 mg, 20 mg
Form: Tablets / Oral solution
Reference Brands: Selzentry (USA), Celsentri (EU)
View Details
Raltegravir
Strength:
100mg, 400 mg, 600mg
Form: Tablets
Reference Brands: Isentress (USA/EU)
View DetailsQuick Response Guaranteed | Verified Suppliers
